在当今医疗领域，创新疗法的出现不断挑战我们的认知，而最新批准的干细胞产品Ryoncil®便是如此。其单次输注的价格高达19.4万美元，这个数字对于许多人来说无疑令人震惊。那么，这样的定价究竟反映了什么样的市场价值与治疗潜力呢？

2月26日，Mesoblast公司公布了Ryoncil的定价。单次静脉输注19.4万美元（2×106MSC/kg）， 完整疗程（需注射8次）费用高达155.2万美元（折合人民币超1100万元），且与体重无关 。与同为先进细胞疗法的百万CAR-T相比，其“天价”不禁引起了行业内的讨论。

Regenerative medicine, a rapidly advancing field, can be generally defined as a therapeutic methodology for the repair, ...

Manufacturing: As a result of FDA approval of RYONCIL in December 2024, the US$23.0 million provision against the value of inventory manufactured and expensed in prior periods was reversed and is now ...

Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013.

Each year, approximately 375 pediatric patients in the U.S. are diagnosed with SR-aGvHD. The cost of treating a child who dies of SR-aGvHD within 12 months of transplant is approximately US$2.5 ...

Mesoblast has set a price for its recently-approved flagship drug, which will go to market over the next few weeks. The post Mesoblast share price rips 12% on financial and operational updates ...